Does antiretroviral therapy reduce hiv-associated tuberculosis incidence to background rates? A national observational cohort study from england, wales, and northern ireland

The Lancet HIV

Volumn 2, Issue 6, 2015, Pages e243-e251

  Gupta, Rishi K ^a,b   Rice, Brian ^b   Brown, Alison E ^b   Thomas, H Lucy ^b   Zenner, Dominik ^a,b   Anderson, Laura ^b   Pedrazzoli, Debora ^b,c   Pozniak, Anton ^d   Abubakar, Ibrahim ^a,b   Delpech, Valerie ^b   Lipman, Marc ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN; AFRICAN CARIBBEAN; ARTICLE; BANGLADESHI; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; ETHNICITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED TUBERCULOSIS; HUMAN; INCIDENCE; INDIAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PAKISTANI; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUBERCULOSIS; UNITED KINGDOM; BLOOD; COMPLICATION; ETHNOLOGY; HIV INFECTIONS; MIDDLE AGED;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; ENGLAND; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NORTHERN IRELAND; TUBERCULOSIS; WALES;

EID: 84947047557     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00063-6     Document Type: Article

References (30)

1. WHO. World Health Organization global TB report 2014. Geneva, Switzerland: World Health Organization. http://www.who.int/tb/ publications/global_report/en/ (accessed Jan 28, 2015).
2. Public Health England. Tuberculosis in the UK 2013 report. 2013. https://www.gov.uk/government/uploads/system/uploads/ attachment_data/fi le/325632/TB_in_the_UK.pdf (accessed Dec 1, 2014).
3. Rice B, Elford J, Yin Z, et al. Decreasing incidence of tuberculosis among heterosexuals living with diagnosed HIV in England and Wales. AIDS 2013; 27: 1151-57.
4. WHO. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva, Switzerland: World Health Organization. http://www.who.int/tb/ publications/2012/tb_hiv_policy_9789241503006/en/ (accessed Jan 28, 2015).
5. Pozniak AL, Coyne KM, Miller RF, et al. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med 2011; 12: 517-24.
6. National Institute for Health and Care Excellence. Tuberculosis clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011. http://www.nice.org.uk/ guidance/cg117/resources/guidance-tuberculosis-pdf (accessed Jan 22, 2015).
7. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009; 30: 685-99, viii.
8. Lawn SD, Myer L, Edwards D, Bekker L-G, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23: 1717-25.
9. Dembélé M, Saleri N, Carvalho ACC, et al. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. Int J Tuberc Lung Dis 2010; 14: 318-23.
10. Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defi c Syndr 2011; 56: 349-55.
11. Gupta A, Wood R, Kaplan R, Bekker L-G, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One 2012; 7: e34156.
12. Naidoo K, Karim QA, Bhushan A, et al. High rates of tuberculosis in patients accessing HAART in rural South Africa. J Acquir Immune Defi c Syndr 2014; 65: 438-46.
13. Grant AD, Bansi L, Ainsworth J, et al. Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS 2009; 23: 2507-15.
14. Moreno S, Jarrin I, Iribarren JA, et al. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. Int J Tuberc Lung Dis 2008; 12: 1393-400.
15. HIV-CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in highincome countries. Clin Infect Dis 2012; 54: 1364-72.
16. Lodi S, del Amo J, d'Arminio Monforte A, et al. Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax 2013; 68: 207-13.
17. Brinkhof MWG, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45: 1518-21.
18. Braitstein P, Brinkhof MWG, Dabis F, et al. Mortality of HIV-1-infected patients in the fi rst year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-24.
19. Sterling TR, Lau B, Zhang J, et al. Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 2011; 204: 893-901.
20. Girardi E, Sabin CA, d'Arminio Monforte A, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41: 1772-82.
21. Karo B, Haas W, Kollan C, Gunsenh eimer-Bartmeyer B, Hamouda O, Fiebig L. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis 2014; 14: 148.
22. Kufa T, Mabuto T, Muchiri E, et al. Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One 2014; 9: e111209.
23. Public Health England. Collaborative Tuberculosis Strategy for England. 2015. https://www.gov.uk/government/uploads/system/ uploads/attachment_data/fi le/403231/Collaborative_TB_Strategy_ for_England_2015_2020_.pdf (accessed April 14, 2015).
24. Story A, Murad S, Roberts W, Verheyen M, Hayward AC. Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 2007; 62: 667-71.
25. Love J, Sonnenberg P, Glynn JR, et al. Molecular epidemiology of tuberculosis in England, 1998. Int J Tuberc Lung Dis 2009; 13: 201-07.
26. Kent RJ, Uttley AH, Stoker NG, Miller R, Pozniak AL. Transmission of tuberculosis in British centre for patients infected with HIV. BMJ 1994; 309: 639-40.
27. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102.
28. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, doubleblind, placebo-controlled trial. Lancet 2011; 377: 1588-98.
29. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet 2014; 384: 682-90.
30. Pareek M, Evans J, Innes J, et al. Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype. Thorax 2013; 68: 221-29.